The drug has been shown to be effective at preventing HIV infection but does not cure an existing HIV infection.

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 ...

In a population of cisgender men, transgender women, transgender men, and gender-nonbinary persons, the incidence of HIV is lower with receipt of twice-yearly subcutaneous lenacapavir.

A new injectable drug for HIV prevention, lenacapavir, is being hailed as a potential game-changer in the fight against the ...

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Health experts say lenacapavir could reduce the number of global HIV infections significantly. But it needs to be cheaper to ...

The drug lenacapavir, developed by Gilead Sciences, provides protection for half a year instead of one day and has performed extremely well in clinical trials.